Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.
PR Newswire - November 8, 1995
Twenty-four HIV-infected patients will receive VIMRxyn in the study which is designed to identify an effective dose with minimal cutaneous photosensitivity. In an earlier trial sponsored by the National Institutes of Health, photosensitivity was found to be a dose-limiting side effect.
The study's principal investigator is Dr. Sricharoen Migasena, director of the Vaccine Trial Centre at Mahidol University in Bangkok. Pharma Bio-Research (Zuidlaren, Netherlands), a leading clinical research organization in Europe, is managing the study.
According to Alfonso J. Tobia, Ph.D., executive vice president at VIMRx, finding the right dose is the next step in the development of VIMRxyn. "Once we have selected an oral dosage we can begin expanded Phase II and multi-centered Phase III trials in the U.S. and abroad."
VIMRx Pharmaceuticals Inc. is developing therapeutic products to fight the spread of viral and retroviral diseases. The in vitro antiviral properties of hypericin were initially documented at the Weizmann Institute of Science in Israel. Further studies and the discovery of the antiviral properties of hypericin were made at NYU Medical Center. VIMRx has exclusive worldwide rights to develop and commercialize hypericin and its derivatives. VIMRx, through its subsidiary, VPI Holdings Limited, has also acquired exclusive worldwide rights to develop and commercialize a new class of therapeutics based upon catalytic oligonucleotides.
CONTACT: Alfonso J. Tobia, Ph.D., Executive Vice President of VIMRx Pharmaceuticals, 203-329-0811; or Investor Relations Counsel: Douglas Johnson, Ph.D., of GreenTree Communications, 800-428-8796/ 08:48 EST
Copyright (c) 1995/PR NewsWire. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, PR Newswire, 810 Seventh Avenue, New York, NY 10019.
951108
PR951111
Copyright © 1995 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .